Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

The Institute for Clinical and Economic Research stands by its assessment that Novartis' yet-to-be-approved gene therapy for spinal muscular atrophy, Zolgensma, shouldn't cost more than $1.5 million. It's a far cry from Novartis' contention that a $4 million to $5 million price would be justified.